Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database

Abstract Background The incidence of pediatric inflammatory bowel disease (IBD) significantly increased recently. Infliximab (IFX) and adalimumab (ADA), both TNF-α inhibitors, are the only FDA-approved treatments for pediatric IBD. Due to the unique physiological and developmental characteristics of...

Full description

Bibliographic Details
Published in:BMC Gastroenterology
Main Authors: Yanhong Deng, Shengying Shi, Senling Feng, Xiangping Tan, Yinling Wang, Jinjin Yin, Shaozhi Liu, Yuanmei Gao
Format: Article
Language:English
Published: BMC 2025-08-01
Subjects:
Infliximab
Adalimumab
Adverse event
Pharmacovigilance
Pediatric
Inflammatory bowel diseases
Online Access:https://doi.org/10.1186/s12876-025-04154-w

Internet

https://doi.org/10.1186/s12876-025-04154-w

Similar Items